Hostname: page-component-77f85d65b8-2tv5m Total loading time: 0 Render date: 2026-03-27T19:21:01.487Z Has data issue: false hasContentIssue false
  • English
  • Français

Head and neck immunoglobulin G4 related disease: systematic review

Published online by Cambridge University Press:  18 December 2018

G Tirelli ,
N Gardenal ,
A Gatto ,
E Quatela  and
G C Del Piero
G Tirelli
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, University of Trieste, Cattinara Hospital, Italy
N Gardenal*
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, University of Trieste, Cattinara Hospital, Italy
A Gatto
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, University of Trieste, Cattinara Hospital, Italy
E Quatela
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, University of Trieste, Cattinara Hospital, Italy
G C Del Piero
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, University of Trieste, Cattinara Hospital, Italy
*
Author for correspondence: Dr Nicoletta Gardenal, Department of Otorhinolaryngology and Head and Neck Surgery, University of Trieste, Cattinara Hospital, Strada di Fiume 447, I-34149, Trieste, Italy E-mail: nicolettagardenal@gmail.com Fax: +39 040 3994180
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Immunoglobulin G4 related disease is a recently described systemic syndrome. The head and neck region is the second most common site for presentation after the pancreas.

Methods

PubMed and the Cochrane Library were searched from 1995 to July 2017 for all the studies on immunoglobulin G4 related disease diagnosed in the head and neck compartment. Patient-specific data were extracted and basic statistical analysis was performed.

Results

Ninety-one patients were identified. Treatment was specified in 76 patients. Twenty patients received surgical treatment, eight of them in association with medical therapy. Fifty-six patients received medical treatment. The disease recurred in 25 per cent of patients treated with surgical treatment alone, in 3.6 per cent of patients treated with medical treatment alone and in 12.5 per cent of patients treated with both. All medical treatment protocols contained high-dose corticosteroids.

Conclusion

Early and correct diagnosis can avoid unnecessary surgical treatment, and glucocorticoid therapy can improve the long-term prognosis.

Keywords

Immunoglobulin GImmune SystemLymph NodesGlucocorticoidsImmunosuppressive Agents

Information

Type
Review Article
Information
The Journal of Laryngology & Otology , Volume 132 , Issue 12 , December 2018 , pp. 1046 - 1050
Copyright
Copyright © JLO (1984) Limited, 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

Dr N Gardenal takes responsibility for the integrity of the content of the paper

References

1Hamano, H, Kawa, S, Horiuchi, A, Unno, H, Furuya, N, Akamatsu, T et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001;344:732–8Google Scholar
2Umehara, H, Okazaki, K, Masaki, Y, Kawano, M, Yamamoto, M, Saeki, T et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 2012;22:1–14Google Scholar
3Stone, JH, Khosroshahi, A, Deshpande, V, Chan, JK, Heathcote, JG, Aalberse, R et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system. Arthritis Rheum 2012;64:3061–7Google Scholar
4Deshpande, V, Zen, Y, Chan, JK, Yi, EE, Sato, Y, Yoshino, T et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012;25:1181–92Google Scholar
5Khosroshahi, A, Stone, JH. A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol 2011;23:57–66Google Scholar
6Cheuk, W, Chan, JK. IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Adv Anat Pathol 2010;17:303–32Google Scholar
7Mulholland, GB, Jeffery, CC, Satija, P, Côté, DW. Immunoglobulin G4-related diseases in the head and neck: a systematic review. J Otolaryngol Head Neck Surg 2015;44:24Google Scholar
8Ferry, JA, Deshpande, V. IgG4-related disease in the head and neck. Semin Diagn Pathol 2012;29:235–44Google Scholar
9Umehara, H, Okazaki, K, Masaki, Y, Kawano, M, Yamamoto, M, Saeki, T et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012;22:21–30Google Scholar
10Wallace, ZS, Deshpande, V, Stone, JH. Ophthalmic manifestations of IgG4-related disease: single-center experience and literature review. Semin Arthritis Rheum 2014;43:806–17Google Scholar
11McNab, AA, McKelvie, P. IgG4-related ophthalmic disease. Part I: background and pathology. Ophthalmic Plast Reconstr Surg 2015;31:83–8Google Scholar
12Inoue, A, Wada, K, Matsuura, K, Osafune, H, Ida, Y, Kosakai, A et al. IgG4-related disease in the sinonasal cavity accompanied by intranasal structure loss. Auris Nasus Larynx 2016;43:100–4Google Scholar
13Beyer, G, Schwaiger, T, Lerch, MM, Mayerle, J. IgG4-related disease: a new kid on the block or an old acquaintance? United European Gastroenterol J 2014;2:165–72Google Scholar
14Lin, W, Lu, S, Chen, H, Wu, Q, Fei, Y, Zhang, X et al. Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. Rheumatology (Oxford) 2015;54:1982–90Google Scholar
15Cheuk, W, Chan, JK. Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity. Semin Diagn Pathol 2012;29:226–34Google Scholar
16Gill, J, Angelo, N, Yeong, ML, McIvor, N. Salivary duct carcinoma arising in IgG4-related autoimmune disease of the parotid gland. Hum Pathol 2009;40:881–6Google Scholar
17Tian, W, Yakirevich, E, Matoso, A, Gnepp, DR. IgG4(+) plasma cells in sclerosing variant of mucoepidermoid carcinoma. Am J Surg Pathol 2012;36:973–9Google Scholar
18Yamamoto, M, Takahashi, H, Tabeya, T, Suzuki, C, Naishiro, Y, Ishigami, K et al. Risk of malignancies in IgG4-related disease. Mod Rheumatol 2012;22:414–18Google Scholar
19Yun, J, Wienholt, L, Adelstein, S. Poor positive predictive value of serum immunoglobulin G4 concentrations in the diagnosis of immunoglobulin G4-related sclerosing disease. Asia Pac Allergy 2014;4:172–6Google Scholar
20Yamamoto, M, Tabeya, T, Naishiro, Y, Yajima, H, Ishigami, K, Shimizu, Y et al. Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol 2012;22:419–25Google Scholar
21Gunasekara, TN, Di Palma, S, Bagwan, IN. IgG4 related sclerosing sialadenitis – a retrospective analysis. Malays J Pathol 2016;38:111–15Google Scholar
22Moriyama, M, Furukawa, S, Kawano, S, Goto, Y, Kiyoshima, T, Tanaka, A et al. The diagnostic utility of biopsies from the submandibular and labial salivary glands in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz's disease. Int J Oral Maxillofac Surg 2014;43:1276–81Google Scholar
23Della-Torre, E, Mattoo, H, Mahajan, VS, Deshpande, V, Krause, D, Song, P et al. IgG4-related midline destructive lesion. Ann Rheum Dis 2014;73:1434–6Google Scholar
24Ebbo, M, Grados, A, Guedj, E, Gobert, D, Colavolpe, C, Zaidan, M et al. Usefulness of 2-[18 F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study. Arthritis Care Res (Hoboken) 2014;66:86–96Google Scholar
25Tirelli, G, Gardenal, N, Del Piero, GC. Neck abscess: an unusual clinical presentation of immunoglobulin G4 related disease. Laryngoscope 2016;126:1114–16Google Scholar
26Hart, PA, Kamisawa, T, Brugge, WR, Chung, JB, Culver, EL, Czakó, L et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013;62:1771–6Google Scholar
27Hart, PA, Topazian, MD, Witzig, TE, Clain, JE, Gleeson, FC, Klebig, RR et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2012;62:1607–15Google Scholar
28Kamisawa, T, Okazaki, K, Kawa, S, Shimosegawa, T, Tanaka, M; Research Committee for Intractable Pancreatic Disease and Japan Pancreas Society. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 2010;45:471–7Google Scholar
29Khosroshahi, A, Carruthers, MN, Deshpande, V, Unizony, S, Bloch, DB, Stone, JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 2012;91:57–66Google Scholar
30Ebbo, M, Daniel, L, Pavic, M, Sève, P, Hamidou, M, Andres, E et al. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore) 2012;91:49–56Google Scholar